TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

KISQALI FEMARA CO-PACK (COPACKAGED)

LETROZOLE Aromatase Inhibitors
Oncology Approved 2017-05-04
6
Indications
--
Phase 3 Trials
1
Priority Reviews
8
Years on Market

Details

Status
Prescription
First Approved
2017-05-04
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: LETROZOLE , RIBOCICLIB SUCCINATE

KISQALI FEMARA CO-PACK (COPACKAGED) Approval History

Loading approval history...

What KISQALI FEMARA CO-PACK (COPACKAGED) Treats

2 indications

KISQALI FEMARA CO-PACK (COPACKAGED) is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Early Breast Cancer
  • Advanced Breast Cancer
Source: FDA Label

Drugs Similar to KISQALI FEMARA CO-PACK (COPACKAGED)

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

KISQALI FEMARA CO-PACK (COPACKAGED) FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Exten...

KISQALI FEMARA CO-PACK (COPACKAGED) Patents & Exclusivity

Latest Patent: Apr 2036
Exclusivity: Sep 2027

Patents (18 active)

US12419894 Expires Apr 14, 2036
US10799506 Expires Apr 14, 2036
US12064434 Expires Apr 14, 2036
US12544380 Expires Aug 7, 2034
US9868739 Expires Nov 9, 2031
US9193732 Expires Nov 9, 2031
US8415355 Expires Mar 13, 2031
US8685980 Expires May 25, 2030
US8962630 Expires Dec 9, 2029
US9416136 Expires Aug 20, 2029
+ 8 more patents

Exclusivity

I-951 Until Sep 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.